Wanjia Group Holdings Limited (HKG:0401)
0.1100
0.00 (0.00%)
Jan 20, 2026, 3:34 PM HKT
Wanjia Group Holdings Revenue
Wanjia Group Holdings had revenue of 85.71M HKD in the half year ending September 30, 2025, a decrease of -8.21%. This brings the company's revenue in the last twelve months to 163.70M, down -4.50% year-over-year. In the fiscal year ending March 31, 2025, Wanjia Group Holdings had annual revenue of 161.69M, down -10.71%.
Revenue (ttm)
163.70M
Revenue Growth
-4.50%
P/S Ratio
0.38
Revenue / Employee
924.88K
Employees
180
Market Cap
61.62M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2025 | 161.69M | -19.40M | -10.71% |
| Mar 31, 2024 | 181.09M | 7.39M | 4.25% |
| Mar 31, 2023 | 173.70M | 18.88M | 12.19% |
| Mar 31, 2022 | 154.82M | 40.74M | 35.71% |
| Mar 31, 2021 | 114.09M | 17.11M | 17.64% |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| JD Health International | 71.34B |
| BeOne Medicines AG | 38.69B |
| Alibaba Health Information Technology | 36.09B |
| Sino Biopharmaceutical | 33.49B |
| CSPC Pharmaceutical Group | 28.65B |
| WuXi Biologics | 21.98B |
| Hansoh Pharmaceutical Group Company | 14.45B |
| Innovent Biologics | 12.52B |